Elucent Medical is a technology company.
Elucent Medical has raised $43.0M across 1 funding round.
Elucent Medical has raised $43.0M in total across 1 funding round.
Elucent Medical is a venture-backed medical device company developing wireless, real-time surgical navigation tools that transform standard instruments into smart ones using In-Body Spatial Intelligence™ (iSi) for precise tumor localization and excision in soft tissues like breasts and lungs.[1][2][3] Its flagship products—the EnVisio® System (including EnVisio X1 under FDA Breakthrough Designation) and SmartClip™—provide continuous 3D awareness of depth, distance, and direction, enabling surgeons to target small lesions accurately while preserving healthy tissue, reducing re-excisions, costs, and radiation exposure.[1][3][4][5] The company serves oncologic surgeons and patients with cancers requiring minimally invasive procedures, addressing the challenge of navigating featureless soft tissues without outdated wire localization methods.[2][3] Growth momentum includes FDA clearance for EnVisio in 2019, Breakthrough Device Designation for EnVisio X1 in May 2025, first clinical uses in 2021, and $30M in growth capital from Trinity Capital.[3][5][7]
Founded in 2014 and headquartered in the Minneapolis area (initially Madison, Wisconsin), Elucent Medical emerged from the need to improve breast cancer biopsy and lumpectomy localization, replacing 75-year-old wire methods with wireless alternatives.[2][3][6] The idea originated with Dr. Lee Wilke, Professor of Surgery at UW-Madison and Director of UW Health’s Breast Center, who envisioned better marking for biopsy sites; she partnered with biotech veterans Laura King (CEO), Dan van der Weide (CTO, Ph.D.), and Dr. Fred Lee Jr., all co-founders of prior venture-backed firm NeuWave Medical.[2][3][6] Early traction hit in January 2020 with Dr. Wilke's involvement and accelerated in January 2021 with the first 20 SmartClip uses at St. Mary’s Hospital near UW-Madison, validating the technology in real procedures.[2] The company expanded focus to lungs, head/neck, and broader soft-tissue applications, earning FDA clearance for EnVisio in 2019.[2][3]
Elucent stands out in surgical guidance through seamless integration and superior precision:
Elucent rides the wave of precision oncology and minimally invasive surgery, where rising cancer incidences (e.g., lung cancer as top killer, high breast cancer costs) demand tools for small-lesion targeting amid soft-tissue challenges.[2][5] Timing aligns with FDA's push for breakthrough innovations in real-time navigation, reducing positive margins and re-operations—key in an era of value-based care prioritizing outcomes over volume.[3][5] Market forces like aging populations, oncology tech investments (e.g., from Baird Capital, Avestria Ventures, Trinity), and wireless medtech adoption favor Elucent, influencing the ecosystem by setting new standards for iSi, potentially expanding to robotics integration and multi-modal imaging.[1][2][5][6][7]
Elucent is poised to disrupt soft-tissue surgery with EnVisio X1's FDA pathway, targeting commercialization amid surging demand for precise, patient-friendly tools—expect broader adoption in breast/lung oncology and thoracic/abdominal expansions.[5][7] Trends like AI-enhanced navigation, value-based reimbursements, and minimally invasive booms will propel growth, evolving Elucent from niche innovator to standard-setter in guided procedures. This builds on its origins in solving wire localization woes, amplifying surgical precision for smarter cancer care.[1][3][5]
Elucent Medical has raised $43.0M in total across 1 funding round.
Elucent Medical's investors include Vensana Capital.
Elucent Medical has raised $43.0M across 1 funding round. Most recently, it raised $43.0M Series C in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $43.0M Series C | Vensana Capital |